MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1055/s-0045-1809350

Медицинская библиотека · South Asian journal of cancer · 2025

A Single-Center, Retrospective, Real-World, Observational Clinical Study to Evaluate the Safety and Efficacy of Abiraterone (Abiratred) in Patients with Metastatic Prostate Cancer.

Danchaivijitr Pongwut, Archwamety Anita, Wongkraisri Concord

СтатьяПеревод пока не подготовлен

Аннотация

BACKGROUND

Prostate cancer ranks as the eighth leading cause of cancer-related mortality in Thailand, exhibiting an average annual percent increase in incidence rates of 2.7%. Abiraterone acetate, an active prodrug of abiraterone, exhibits potent inhibitory activity against the enzyme CYP17A1, a crucial component in the androgenic biosynthetic cascade. This study was designed to evaluate the safety and efficacy of generic abiraterone (Abiratred) in treating metastatic prostate cancer within a real-world, retrospective observational context.

MATERIALS AND

METHODS

Thirty-five patients diagnosed with metastatic prostate cancer who underwent abiraterone treatment at Siriraj Hospital in Thailand were enrolled in the study. Data encompassing demographics, medical history, general examination, vital signs, comorbidities, health status, and prostate cancer-related characteristics were collected. The primary outcome measure was the prostate-specific antigen (PSA) response rate (defined as a ≥ 50% decrease in PSA levels from baseline), and secondary outcomes encompassed assessing PSA progression-free survival (PFS), disease control rate (DCR), and evaluating safety.

RESULTS

Among the 35 patients, 23 (65.7%) exhibited a PSA response. The median PSA PFS at 6 months was 65.6% (21 out of 35 patients). The DCR was determined to be 71.4% (25 out of 35 patients), with 19 (54.3%) patients experiencing stable disease and 6 (17.1%) patients showing a partial response. Adverse events were observed in 5 (14.3%) patients, but there were no deaths related to abiraterone.

CONCLUSION

This real-world study provides evidence that generic abiraterone (Abiratred) is both well-tolerated and effective for patients with advanced or metastatic prostate cancer, making it a promising option in real-world clinical settings.

Для цитирования: Danchaivijitr Pongwut, Archwamety Anita, Wongkraisri Concord. A Single-Center, Retrospective, Real-World, Observational Clinical Study to Evaluate the Safety and Efficacy of Abiraterone (Abiratred) in Patients with Metastatic Prostate Cancer.. South Asian journal of cancer. 2025. DOI: 10.1055/s-0045-1809350.
Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.